Phase I Escalation and Expansion Study of Bemarituzumab (FPA144) in Patients With Advanced Solid Tumors and FGFR2b-Selected Gastroesophageal Adenocarcinoma (vol 38, pg 2418, 2020)-MedSci.cn

Phase I Escalation and Expansion Study of Bemarituzumab (FPA144) in Patients With Advanced Solid Tumors and FGFR2b-Selected Gastroesophageal Adenocarcinoma (vol 38, pg 2418, 2020)

Catenacci, DVT; Rasco, D; Lee, J; Rha, SY; Lee, KW; Bang, YJ; Bendell, J; Enzinger, P; Marina, N; Xiang, H; Deng, W; Powers, J; Wainberg, ZA

Catenacci, DVT (corresponding author), Univ Chicago, Chicago, IL 60637 USA.

JOURNAL OF CLINICAL ONCOLOGY, 2021; 39 (3): 258

科室
- - 订阅+
  - 更多科室
工具
服务